Volatility is the name of the game. Uncertainty breeds caution and is not a good setup for investments. You are not going to build out capacity if you do not know future costs or demand. This is why everyone is fearing a recession and the move into a bear market. Bear markets are quite dangerous […]
April 9th Biotech Update
In some ways it looked like the sector would be able to bottom or recover a little but even when we saw some green in the broader market the sector floundered. Pick a reason why. Rates are going up even thought the economy could be entering a recession. You have economic uncertainty. You have regulatory […]
April 4th Biotech Update
So, it has not been the best end to the week (to say the least). If we want to try and put the best spin on it, then I would say that the sector has outperformed. If you would have told me that the broader markets were going to be this weak, then I would […]
April 1st Biotech Update
So I think it is safe to say that the sector has broken down. While rates have become a more favorable backdrop, the regulatory uncertainty combined with political risks have overwhelmed everything that could have boosted the sector. I do not think we will be able to get into a bull market until that resolves. […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
